Pushing AR Toward Better Outcomes In Breast And Prostate Cancers
Funder
National Health and Medical Research Council
Funding Amount
$998,754.00
Summary
Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives ....Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.Read moreRead less
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
Engineered topological nanostructures – a new frontier in materials design. The aim of engineering and utilising topological defects such as domain walls and and skyrmions in functional materials is currently receiving tremendous attention. Their significance lies in a plethora of fascinating phenomena for fundamental research and future technological applications in nanoelectronics. One frontier area of research is negative capacitance nanoelectronics using such materials, carrying the prospect ....Engineered topological nanostructures – a new frontier in materials design. The aim of engineering and utilising topological defects such as domain walls and and skyrmions in functional materials is currently receiving tremendous attention. Their significance lies in a plethora of fascinating phenomena for fundamental research and future technological applications in nanoelectronics. One frontier area of research is negative capacitance nanoelectronics using such materials, carrying the prospect of revolutionizing ultralow energy electronics, which will be developed here. The project's expected outcomes are new concepts for the synthesis and design of topological nanostructures for such applications. The utilization of these materials will benefit efficient controllable functionality for future nanoelectronics.Read moreRead less
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revol ....ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research activity in Australia, uniting universities, research agencies, institutes and companies. The expected outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bio-nano-interface.Read moreRead less
Special Research Initiatives - Grant ID: SR0354640
Funder
Australian Research Council
Funding Amount
$10,000.00
Summary
Young Investigators Network on Next Generation Electronic Devices. This initiative will build an active, dynamic and strongly interdisciplinary network of young Australian scientists (most awarded their Ph.D. after 1985) working on the development of innovative electronic devices - a national research priority area with enormous economic and technological opportunity. The network will enable a nationally coordinated, internationally competitive approach that capitalizes on untapped opportunitie ....Young Investigators Network on Next Generation Electronic Devices. This initiative will build an active, dynamic and strongly interdisciplinary network of young Australian scientists (most awarded their Ph.D. after 1985) working on the development of innovative electronic devices - a national research priority area with enormous economic and technological opportunity. The network will enable a nationally coordinated, internationally competitive approach that capitalizes on untapped opportunities, utilises existing/emerging Australian expertise and develops strong supporting links with similar networks overseas. The initiative will produce a public showcase of Australian strengths and opportunities in this field, and enable stronger collaborations and cooperative logistics management through the development of a dedicated network management website.Read moreRead less
An In Depth Analysis Of Clinical And Virological Outcomes Of 2 Strategies For The Antiretroviral Salvage Of First-line Regimen Virological Failure For HIV-1 Infection Tested In An Australian-led Randomised, International, Multi-centre Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The recently completed Australian-led SECOND-LINE trial is the first high quality study to provide reliable evidence for policy recommendations for the composition of anti-HIV drug cocktails after standard initial treatment has failed. This award will support the researcher in further refining our understanding of how to manage second-line therapy including proposals to test the use of low-cost technologies for application in resource-limited settings where the majority of people with HIV live.